ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
2021 Key Events
The National Hospital in
Denmark (Rigshospitalet) and
Lundbeck announced a partnership to
find new ways to treat brain diseases.
Lundbeck announced a strategic
partnership with Rgenta Therapeutics
to discover therapies targeting
ribonucleic acid (RNA)
regulation and splicing of
disease-causing genes.
Because COVID-19 restrictions
prevented corporate participation in
the Copenhagen Pride Parade,
Lundbeck held its own Pride Parade,
celebrating the diversity of our
workforce.
Lundbeck announced the
launch of a phase II study
for potential new treatment of multiple
system atrophy (MSA).
7/111
Lundbeck reports positive results for
VyeptiⓇ from the DELIVER study in
patients with migraine and prior
preventive treatment failures.
vyepti
Lundbeck made the decision to
continue the phase III clinical trial for
treatment of agitation in patients
with Alzheimer's-type dementia.
Shipment of first Lundbeck
product donations to IHP partner
clinics in Lebanon, Gaza and
the West Bank was completed.
Lundbeck announced a collaboration
with Inscopix to leverage
sophisticated camera technology to
map the brain on a neuronal level.
Lundbeck announced the
launch of a phase II study for
potential migraine prevention
treatment.
Lundbeck's product VyeptiⓇ was
approved by health authorities
in Canada, the U.A.E., Kuwait,
Switzerland, Singapore
and Australia.
Across the globe, Lundbeck
colleagues recognized World Mental
Health Day and recommitted to
fighting stigma and raising
awareness of inequalities
in mental healthcare.
Lundbeck announced that VyeptiⓇ is
recommended for approval in the EU
by the Committee for Medicinal
Products for Human Use (CHMP)
for the preventive treatment of
migraine in adults.
Lundbeck announced a detailed action
plan to reduce emissions and set
15-year climate target towards
achieving net-zero carbon emissions
across the entire value chain.
Lundbeck convened nearly 80
advocacy groups from more than 20
countries for the annual #1 Voice
Summit, providing participants an
opportunity to share best practices
and collaborate on how to amplify the
voices of people with brain disease.
Supplemental New Drug Application
(SNDA) approved for RexultiⓇ to treat
schizophrenia in pediatric patients
ages 13-17.
Through an agreement with AprilBio,
Lundbeck expanded its expertise in
neuroimmunology, extended our
neuroinflammation platform and
gained rights to an innovative
phase-I-ready biotherapeutic
candidate.
Lundbeck became a member
of the Biopharma Sustainability
Roundtable.View entire presentation